Alveus Therapeutics

Philadelphia, PA · Founded 2023 · Privately Held (backing)

Developer of biological and small-molecule treatments designed for metabolic disease management. Alveus Therapeutics is based in Philadelphia, PA and was founded in 2023. It was valued at $275 million at its early-stage round in Feb 2026, the last priced event on record. It has raised $202 million across 1 recorded round; the latest was a $56.9 million later-stage round in Dec 2025.

PMV mark · valuation
$275.2M
Oct 2026
Priced at
its early-stage round
Feb 2026
Total raised
$202.0M
Last round
Later Stage VC
Dec 2025
What is Alveus Therapeutics worth?
$275.2MPrivateMarketView mark · Oct 2026

Valued at $275.2M at its early-stage round, Feb 2026. Nothing has traded since.

Free account
More of Alveus Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Alveus Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Alveus Therapeutics funding history

1 rounds
DateRoundRaisedPost-money
Dec 2025Later Stage VC$56.9M▮
Unlock post-money valuations

Membership and data by Private Market View

Alveus Therapeutics valuation

Alveus Therapeutics was valued at $275 million at its early-stage round in Feb 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Alveus Therapeutics raised?

Alveus Therapeutics has raised $202 million in total; 1 of its rounds is on record. The largest on record was a $56.9 million later-stage round in Dec 2025.

How Alveus Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Alveus Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Alveus Therapeutics

What is Alveus Therapeutics worth?
Alveus Therapeutics is valued at $275.2M as of Oct 2026. Valued at $275.2M at its early-stage round, Feb 2026. Nothing has traded since.
How much has Alveus Therapeutics raised?
Alveus Therapeutics has raised $202.0M in total funding across 1 recorded rounds.
When did Alveus Therapeutics last raise?
Alveus Therapeutics last raised in Dec 2025 (Later Stage VC), raising $56.9M.